The U.S. Food & Drug Administration (FDA) granted accelerated approval to the drug enfortumab vedotin (EV) to treat adult patients with advanced urothelial or bladder cancer.Article Correctness Is Author's Responsibility: Backed by Yale Cancer Center research, FDA approves new drug for advanced bladder cancer
The U.S. Food & Drug Administration (FDA) granted accelerated approval to the drug enfortumab vedotin (EV) to treat adult patients with advanced urothelial or bladder cancer.
